title: omalizumab (Xolair) and chronic spontaneous urticaria. Too many adverse effects and uncertainties.
abstract: Omalizumab has only modest and transient symptomatic efficacy when an antihistamine is ineffective. Its adverse effects can be severe, and its safety during long-term use is uncertain. Omalizumab is not better than a corticosteroid.
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D002908:Chronic Disease; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D000069444:Omalizumab; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014581:Urticaria / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069444:Omalizumab